1Q preview: AbbVie, Amgen, AstraZeneca, Biogen, Lilly, Novartis, Roche
This article was originally published in Scrip
Johnson & Johnson set the tone for the first-quarter pharma financial reporting season on 14 April when it reported a 4% drop in sales due to currency fluctuations, although pharma beat expectations.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.